The stock of Arcus Biosciences Inc. (RCUS) advanced 17.95% in after-hours trading Wednesday to $27.60. Arcus stock gained 2.86% in the regular session to conclude the trading at $23.40. RCUS stock price fluctuated between $22.63 and $23.91.

There were 0.97 million shares of RCUS stock traded on the day, above its 100-day daily average of 0.55 million shares. In the last five days, RCUS stock has declined by -2.50%, and in the past month, it has gone down by -4.68%. Positive results of a clinical study lifted the RCUS stock.

What was the purpose of RCUS performing that activity?

In addition to offering oncology-focused therapies, Arcus Biosciences develops novel combinations in order to address unmet medical needs and discover new therapies. There are several molecules being developed by RCUS at the moment. Etrumadenant (AB928) is the RCUS’ first dual adenosine receptor antagonist to enter patient care. RCUS has been evaluating it in Phase 2 and 1b clinical trials across multiple indications, including prostate, lung, and pancreatic cancer.

Arcus announced that its Phase 2 ARC-7 study, which involves three arms, showed encouraging clinical activity in both arms based on domvanalimab.

• The positive results were reported when the combinations were used as a first-line treatment (in the first week) for people with metastatic, non-small cell lung cancer (NSCLC).
• Zimberelimab monotherapy showed activity similar to that of anti-PD-1 antibodies marketed by other companies.
• By the time of the study’s data cutoff, no unexpected safety signals had been observed, and each arm’s safety profile remained consistent with that of known immune checkpoint inhibitors in such an environment.
• As planned, RCUS will continue all three arms of the ARC-7 trial, as well as enroll participants in the ongoing Phase 3 registrational study of ARC-10.
• ARC-7 data will be presented to a medical conference later this year by RCUS.
• Domvanalimab is exclusively available for co-development and co-commercialization through RCUS partner Gilead Sciences.
• Later this year, RCUS expects to decide whether to participate in the anti-TIGIT program.
• As part of their Phase 3 studies, Arcus and Gilead will explore options for combinations containing both domvanalimab and etrumadenant.

RCUS moves forward with its ARC-7 study:

The data analysis for the ongoing ARC-7 study by Arcus (RCUS) revealed that its anti-TIGIT domvanalimab-based combinations showed clinical promise. Zimberelimab monotherapy led to similar results as those observed in studies of marketed anti-PD-1 antibodies. On the horizon, RCUS plans to enroll all domvanalimab studies, explore combinations of domvanalimab and etrumadenant, and begin Phase 3 trials for domvanalimab in multiple cancer types.